{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:09:51Z","timestamp":1792440591193,"version":"4.5.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The cytochrome P450 2D6 (CYP2D6) is an enzyme involved in the oxidative biotransformation of various widely used drugs, including paroxetine, a substrate and strong inhibitor of the enzyme. The aim is to report on a case of protracted intoxication with paroxetine after a single overdose in a genotype-predicted intermediate CYP2D6 metabolizer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Observation<\/jats:title><jats:p>A 49-year-old man was receiving chronic treatment for more than 6\u00a0years with paroxetine 60\u00a0mg\/day for an indication of agoraphobia. The patient ingested fifty 20\u00a0mg tablets of paroxetine in a suicide attempt. The toxic plasma level, accompanied by delirium, persisted for approximately 1\u00a0month after the overdose. According to the genotype profile, the patient was evaluated as an intermediate metabolizer with reduced CYP2D6 enzyme activity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>As a consequence of the suicide attempt with overdose and the chronic paroxetine treatment that preceded it, phenoconversion to a poor metabolizer with very low CYP2D6 enzyme activity is suggested as contributing to an extremely long intoxication accompanied by delirium. Prolonged monitoring over a standard 24\u00a0h of both physical symptoms and drug plasma levels, together with a genetic profile assessment and phenoconversion consideration, is recommended after a single overdose in patients chronically treated with paroxetine.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1444857","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T05:22:38Z","timestamp":1725427358000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Case report: Therapeutic drug monitoring and CYP2D6 phenoconversion in a protracted paroxetine intoxication"],"prefix":"10.3389","volume":"15","author":[{"given":"Alena","family":"Damborsk\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Han\u00e1kov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Pindurov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate\u0159ina","family":"Horsk\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"key":"B1","first-page":"42","article-title":"SSRI safety in overdose","volume":"59","author":"Barbey","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1046\/j.0306-5251.2001.01548.x","article-title":"Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs","volume":"53","author":"Bertilsson","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/cpt.2903","article-title":"Clinical pharmacogenetics implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants","volume":"114","author":"Bousman","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1517\/14622416.3.2.229","article-title":"CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants","volume":"3","author":"Bradford","year":"2002","journal-title":"Pharmacogenomics"},{"key":"B5","first-page":"237","article-title":"Pharmacogenetic testing and its current use in psychiatric practice","volume":"118","author":"\u010ce\u0161kov\u00e1","year":"2022","journal-title":"Ceska Slov. Psychiatr."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1249164","DOI":"10.3389\/fgene.2023.1249164","article-title":"Pharmacogenetics and phenoconversion: the influence on side effects experienced by psychiatric patients","volume":"14","author":"den Uil","year":"2023","journal-title":"Front. Genet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/cpt.910","article-title":"The Pharmacogene variation (PharmVar) Consortium: incorporation of the human cytochrome P450 (CYP) allele nomenclature database","volume":"103","author":"Gaedigk","year":"2018","journal-title":"Clin. Pharm. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/gim.2016.80","article-title":"Prediction of CYP2D6 phenotype from genotype across world populations","volume":"19","author":"Gaedigk","year":"2017","journal-title":"Genet. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/JCP.0000000000000640","article-title":"A validation study of the international consensus diagnostic criteria for neuroleptic malignant syndrome","volume":"37","author":"Gurrera","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2217\/pgs-2023-0100","article-title":"The role of phenoconversion in the pharmacogenetics of psychiatric medication","volume":"24","author":"Hahn","year":"2023","journal-title":"Pharmacogenomics"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1007\/s00204-020-02936-7","article-title":"Inhibition and induction of CYP enzymes in humans: an update","volume":"94","author":"Hakkola","year":"2020","journal-title":"Arch. Toxicol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1097\/00007691-200208000-00017","article-title":"Very long half-life of paroxetine following intoxication in an extensive cytochrome P4502D6 metabolizer","volume":"24","author":"Hilleret","year":"2002","journal-title":"Ther. Drug Monit."},{"key":"B14","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1097\/FTD.0000000000001096","article-title":"Impact of CYP2D6 genotype on paroxetine serum concentration","volume":"45","author":"Hole","year":"2023","journal-title":"Ther. Drug Monit."},{"key":"B15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/sj.tpj.6500285","article-title":"Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity","volume":"5","author":"Ingelman-Sundberg","year":"2005","journal-title":"Pharmacogenomics J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.3390\/jcm9092890","article-title":"Phenoconversion of cytochrome p450 metabolism: a systematic review","volume":"9","author":"Klomp","year":"2020","journal-title":"J. Clin. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41398-020-01129-1","article-title":"Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19","volume":"11","author":"Koopmans","year":"2021","journal-title":"Transl. Psychiat"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/cpt.2146","article-title":"Impact of acute inflammation on cytochromes P450 activity assessed by the Geneva cocktail","volume":"109","author":"Lenoir","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/clpt.2008.302","article-title":"Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics","volume":"85","author":"Morgan","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00204-008-0332-8","article-title":"Inhibition and induction of human cytochrome P450 enzymes: current status","volume":"82","author":"Pelkonen","year":"2008","journal-title":"Arch. Toxicol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1097\/00008571-200010000-00001","article-title":"Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6","volume":"10","author":"Raimundo","year":"2000","journal-title":"Pharmacogenetics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13054-020-02915-5","article-title":"Revisited: therapeutic and toxic blood concentrations of more than 1,100 drugs and other xenobiotics","volume":"24","author":"Schulz","year":"2020","journal-title":"Crit. Care."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1178646919873925","DOI":"10.1177\/1178646919873925","article-title":"Serotonin syndrome: pathophysiology, clinical features, management, and potential future directions","volume":"12","author":"Scotton","year":"2019","journal-title":"Int. J. Tryptophan. Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/clpt.1992.23","article-title":"The relationship between paroxetine and the sparteine oxidation polymorphism","volume":"51","author":"Sindrup","year":"1992","journal-title":"Clin. Pharmacol. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/01.fpc.0000239974.69464.f2","article-title":"CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure","volume":"17","author":"Sistonen","year":"2007","journal-title":"Pharmacogenet. Genom."},{"key":"B26","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/jat\/22.6.541","article-title":"Distribution of paroxetine in three postmortem cases","volume":"22","author":"Vermeulen","year":"1998","journal-title":"J. Anal. Toxicol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.toxlet.2021.07.019","article-title":"OpenCYP: an open source database exploring human variability in activities and frequencies of polymophisms for major cytochrome P-450 isoforms across world populations","volume":"350","author":"Vichi","year":"2021","journal-title":"Toxicol. Lett."},{"key":"B28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00210-003-0832-2","article-title":"Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry","volume":"369","author":"Zanger","year":"2004","journal-title":"N-S Ar. Pharmacol."},{"key":"B29","first-page":"103","article-title":"Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects","volume":"22","author":"\u017dourkov\u00e1","year":"2003","journal-title":"Gen. Physiol. Biophys."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1444857\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T05:22:50Z","timestamp":1725427370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1444857\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":29,"alternative-id":["10.3389\/fphar.2024.1444857"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1444857","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,4]]},"article-number":"1444857"}}